Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT

Annals of Thoracic Surgery

Volumn 70, Issue 3, 2000, Pages 866-871

  Dyke, Cornelius M ^a,b,c,d   Bhatia, Devinder ^a,b,c,d   Lorenz, Todd J ^a,b,c,d   Marso, Steven P ^a,b,c,d   Tardiff, Barbara E ^a,b,c,d   Hogeboom, Charissa ^a,b,c,d   Harrington, Robert A ^a,b,c,d  

^a Sanger Clinic   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANGINA, UNSTABLE; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 0033807653     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01654-4     Document Type: Article

References (26)

1. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
2. Randomised placebo-controlled trial of the effect of eptifibatide on complications of percutaneous coronary interventions IMPACT-II II
3. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
4. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
5. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
6. Preoperative use of enoxaparin and tirofiban: Possible association with increased bleeding postbypass
7. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization: Management strategies for the cardiac surgeon
8. Blood use in emergency coronary artery bypass after receipt of abciximab during angioplasty
9. Thrombosis in unstable angina
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
12. Complimentary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptrors
13. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
14. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
15. Have PTCA failures requiring emergent bypass operation changed?
16. Emergency bypass surgery for failed coronary interventions
17. Reduction in angioplasty complications after the introduction of coronary stents: Results from a consecutive series of 2242 patients
18. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Epic Investigators
19. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
20. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery
21. Safety of glycoprotein IIb/IIIa inhibitors: A heart surgeon's perspective
22. Reopro removal during cardiopulmonary bypass using a hemoconcentrator
23. Blood transfusion in emergency coronary artery bypass: Regression analysis
24. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab?
25. Integrelin prevents prolonged bleeding times after cardiopulmonary bypass